RxDoctor Payments Data

Benjamin Benhuri

Internal Medicine · New York, NYNPI 1376031690

Payments from drug & device makers

$4,268in general payments, 2019–2025

Across 71 payments — averaging $60.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3K
  • Novo Nordisk$350
  • Idorsia Pharmaceuticals US Inc$280
  • Viiv Healthcare Company$264
  • Astellas Pharma US Inc$208
  • Gilead$94
  • plus $353 from 9 others

What the payments were for

  • Speaking & faculty fees$2,70063%
  • Food & beverage$1,56837%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,268 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$57,523
Medicare patients
116
Services billed
825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide93$95,391
OzempicSemaglutide44$46,752
TrulicityDulaglutide21$20,310
Praluent PenAlirocumab23$16,895
EliquisApixaban20$15,643
XareltoRivaroxaban17$14,927
SynjardyEmpagliflozin/Metformin Hcl19$9,585
Rosuvastatin Calcium89$1,593
Atorvastatin Calcium106$1,083
Pregabalin34$998
Ketoconazole27$942
Potassium Chloride15$768
Bupropion XlBupropion Hcl36$764
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide11$764
Gabapentin63$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$64$115,702114 claims
Novo NordiskOzempic$350$46,75244 claims
PfizerEliquis$2,720$15,64320 claims
Johnson & JohnsonXarelto$43$14,92717 claims
Boehringer IngelheimSynjardy$26$9,58519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →